Truist lowered the firm’s price target on Boston Scientific (BSX) to $113 from $120 and keeps a Buy rating on the shares as part of a broad ...

Despite a shaky quarter due to U.S.-China trade tensions and a 6% dip in stock price, Boston Scientific still flexed its ...

Boston Scientific (NYSE:BSX) experienced a 6% decline in stock price over the last quarter, amid a period of market uncertainty driven by new tariffs imposed by the U.S. and retaliatory measures from ...

Cartesian Therapeutics Inc. followed up December’s phase IIb data with more good news regarding Descartes-08, offering 12-month efficacy and safety results that whetted Wall Street’s appetite for the ...

Pulsed field ablation using Boston Scientific Corp.’s Farapulse system was non-inferior and even superior, slightly, to Medtronic plc’s Artic Front Advance cardiac cryoablation system in treating ...

Atrial tachyarrhythmia recurred in 39 patients treated with Boston Scientific’s Farapulse PFA device, while 53 people had recurrence in the Medtronic cryoablation group.

The SINGLE SHOT CHAMPION study increases momentum for PFA as a first-line option for pulmonary vein isolation, say experts.

Boston Scientific (NYSE: BSX) announced new study findings demonstrating the superiority of its Farapulse pulsed field ...

Abbott has trailed medtech competitors in bringing a PFA device to market, but now plans to accelerate its European rollout in the second half of this year, after beginning with EU physicians familiar ...

Abbott is joining the worldwide race to make pulsed field ablation the standard procedure for atrial fibrillation with an ...

With CE marking, Abbott muscles in amongst other medtech stalwarts in the European PFA market. Boston Scientific has had its Farapulse technology on the market since 2021 while Medtronic and Johnson & ...